8-K 1 corcepttherapeutics8k.htm CORCEPT THERAPEUTICS 8-K
`
`Page 1 of 2
`
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`Washington, D.C. 20549
`
`FORM 8-K
`
`CURRENT REPORT
`
`Pursuant to Section 13 or 15(d) of the
`Securities Exchange Act of 1934
`
`Date of Report: February 17, 2012
`(Date of earliest event reported)
`
`Corcept Therapeutics Incorporated
`(Exact name of registrant as specified in its charter)
`
`DE
`(State or other jurisdiction
`of incorporation)
`
`000-50679
`(Commission File
`Number)
`
`77-0487658
`(IRS Employer
`Identification Number)
`
`149 Commonwealth Drive, Menlo Park, CA
`(Address of principal executive offices)
`
`94025
`(Zip Code)
`
`650-327-3270
`(Registrant's telephone number, including area code)
`
`Not Applicable
`(Former Name or Former Address, if changed since last report)
`
`Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
`the registrant under any of the following provisions:
`
`(cid:134) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
`(cid:134) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
`(cid:134) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2
`(b))
`(cid:134) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4
`(c))
`
`Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal
`Officers
`
`On February 21, 2012, our Board of Directors approved cash bonus payments to our officers and employees in
`recognition of the approval by the U.S. Food and Drug Administration (FDA) of Korlym™ (mifepristone) 300 mg
`Tablets, which is discussed in Item 8.01 below.
`
`The bonus amounts approved for our named executive officers and the Chairman of our Board are as follows:
`
`https://www.sec.gov/Archives/edgar/data/1088856/000110262412000138/corcepttherapeut...
`
`4/25/2019
`
`1
`
`TEVA1044
`
`

`

`Page 2 of 2
`
` Amount of
` Name Title Bonus
`----------------------- ------------------------------------------------------- ----------
`Joseph K. Belanoff, M.D. Chief Executive Officer $481,097
`Robert L. Roe, M.D. President and Secretary $443,369
`James N. Wilson Chairman of the Board $192,439
`Steven Lo Vice President, Commercialization $159,135
`G. Charles Robb Chief Financial Officer $77,250
`Anne M. LeDoux Vice President, Controller and Chief Accounting Officer $70,232
`
`Item 8.01. Other Events
`
`In a press release issued on February 17, 2012, we announced that the FDA has approved Korlym™ (mifepristone)
`300 mg Tablets as a once-daily oral medicine to control hyperglycemia secondary to hypercortisolism in adult
`patients with endogenous Cushing's syndrome who have diabetes mellitus type 2 or glucose intolerance and have
`failed surgery or are not candidates for surgery.
`
`The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
`reference.
`
`Item 9.01. Financial Statements and Exhibits
`
`(a) Financial statements:
` None
`(b) Pro forma financial information:
` None
`(c) Shell company transactions:
` None
`(d) Exhibits
` 99.1 Press Release of Corcept Therapeutics Incorporated dated February 17, 2012
`
` Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
`be signed on its behalf by the undersigned hereunto duly authorized.
`
`SIGNATURE
`
`Dated: February 24, 2012
`
`CORCEPT THERAPEUTICS INCORPORATED
`
`By: /s/ G. Charles Robb
` G. Charles Robb
`Chief Financial Officer
`
`Exhibit Index
`
`Exhibit No.
`99.1
`
`Description
`Press Release of Corcept Therapeutics Incorporated dated
`February 17, 2012
`
`https://www.sec.gov/Archives/edgar/data/1088856/000110262412000138/corcepttherapeut...
`
`4/25/2019
`
`2
`
`